A simple GLP-1 stock strategy: among LLY and NVO, pick the calmer one based on 10-day volatility and invest 100% in that single stock; no automatic rebalancing.

- You’re investing in GLP-1 drug stocks, not an ETF in the strict sense. - The two candidates are LLY (Eli Lilly) and NVO (Novo Nordisk ADR). - The rule looks at the last 10 trading days and measures how much the price moved each day (volatility). - It picks the stock with the smallest volatility (the calmest mover) and puts 100% of the allocation into that one. - Rebalancing is not performed automatically (rebalance: none). The 0.1 corridor width is noted but not acted upon since there is no automatic rebalance. - Result: a simple, fixed exposure to GLP-1 drugs via either LLY or NVO, depending on which has been less volatile recently. - Quick context: GLP-1 drugs include medications like diabetes treatments; LLY and Novo Nordisk are two major players in that space. LLY is a US company; NVO is a Danish company (ADR trades in USD). - Risks: concentration risk (only two names considered); potential currency risk for NVO; volatility-based signals can mislead during sudden market moves; no automatic protection if the calm stock stops being the calm stock. - In short: a minimalistic, single-stock GLP-1 exposure chosen by recent price stability, with no automatic drift into other assets.

Focused GLP-1 pick with strong out-of-sample results: ~33.8% annualized return vs ~17% for the S&P, Sharpe ~0.95, Calmar ~1.40, and a simple rule that buys the calmer stock (LLY vs NVO). Simplicity with outsized upside.